In addition to its role in restoring MHC-I expression, EZH2 inhibitors may have further tumor-suppressive effects on SCLC through broader transcriptional reprogramming, which includes the hyperactivation of ribosome biogenesis, epithelial-mesenchymal transition, and MYC targets (Supplementary Fig. S9a–d). This evidence concerns the gene EZH2 and small cell lung carcinoma.